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INTRODUCTION
Sunitinib is an inhibitor of platelet-derived growth factors receptor (PDGFR) and vascular
endothelial growth factor receptor-2 (VEGFR2) tyrosine-kinase activities, and it is registered for
the treatment of metastatic renal cell carcinoma (mRCC). Indeed, sunitinib 50mg/day for 28 days
every 6 weeks is effective against mRCC and induces significant improvements in progression-free
and overall survival (PFS and OS, respectively) with respect to interferon-α and interleukin-2,
even in cytokine-resistant tumors (Motzer et al., 2006a,b; Motzer et al., 2007). Moreover, in some
patients (30–50%) sunitinib efficacy is counterbalanced by toxicities (Najjar et al., 2014), which
are mainly represented by thrombocytopenia (10%), fatigue (9%), asthenia, neutropenia, and
hand-foot syndrome (each 7%) (Gore et al., 2015). Toxic effects usually worse between weeks 3 and
4 of therapy, requiring treatment interruption in approximately one-third of patients (van der Veldt
et al., 2008; Najjar et al., 2014). The most severe toxicities are associated with low body surface area,
older age, and female gender (van der Veldt et al., 2008). Intriguingly, those three factors could be
potentially related to increased sunitinib exposure, because the drug is administered as a fixed dose
without any adjustment. Indeed, the apparent drug clearance was slightly reduced (approximately
8%) in women with respect to men, while the body weight influenced the apparent volume of
distribution (Houk et al., 2009). Those results could be the basis for patients’ stratification, but the
individualization of the dose appeared to be difficult because those variables were clinically evident
only in combination (i.e., a thin woman) and the inter-patient variability in pharmacokinetic
parameters was about 40–60% (Houk et al., 2009). The third obstacle to dose individualization
is represented by the non-linear pharmacokinetics of sunitinib, “making dose-response modeling
challenging” (Houk et al., 2010).
Therefore, the occurrence of moderate-to-severe toxicities seems related to changes/alterations
in drug pharmacokinetics in particular subgroups of patients, but dose individualization seems
still difficult. In the very recent past, several studies have described a modified schedule for the
administration of sunitinib, 50mg/day for 14 days every 3 weeks (2/1 schedule) instead of the
standard 4/2 schedule (4 weeks on treatment and 2 weeks of rest). The new schedule has the same
dose intensity with respect the classical one, but tolerability has significantly increased (Bracarda
et al., 2015). Those evidence and hypothesis find solid pharmacological bases.
PHARMACOKINETICS AND PHARMACODYNAMICS OF
SUNITINIB IN mRCC
The modulation of molecular targets (i.e., the inhibition of VEGFR2 and PDGFR) in preclinical
model was dependent on the dose (Mendel et al., 2003). Doses lower than 80mg/kg were unable to
completely inhibit receptor activation, and that effect disappeared within 8–12 h from the exposure.
However, sunitinib did not require the constant inhibition of both receptors to exert a potent
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antitumor effect (Mendel et al., 2003). Indeed, the vascular
permeability was highly inhibited hours after the cessation
of sunitinib treatment while the standard dose of 50mg/day
resulted in plasma concentrations within the target interval of
50–100 ng/mL (Faivre et al., 2006) that were associated with
therapeutic benefits (Gore et al., 2015).
In mRCC patients who received sunitinib 50mg/day
according to the 4/2 schedule, four soluble biomarkers of
sunitinib activity were investigated on days 1 and 28 of each
cycle (Deprimo et al., 2007). At the end of the first cycle,
plasma concentrations of VEGF and placental growth factor
(PlGF) were increased, whereas those of soluble receptors
of VEGF (namely sVEGFR2 and sVEGFR3) were decreased
with respect to baseline. Of importance, the concentrations
of the four soluble biomarkers returned to the baseline values
after 2 weeks of rest, suggesting that these effects lasted for a
period of time after cessation of drug administration (Deprimo
et al., 2007). According to that long-lasting effect of sunitinib,
the drug was administered as a neoadjuvant treatment at the
dose of 50mg/day and tumors were excised at various time
intervals from the stop of drug intake (Griffioen et al., 2012).
Interestingly, biomarkers of angiogenesis, such as circulating
endothelial cells and angiopoietin plasma concentrations,
rapidly increased after chemotherapy discontinuation, whereas
tumor microvessel density remained stable for a long period
(approximately 3 weeks) (Griffioen et al., 2012). For sake
of completeness, the discontinuation of sunitinib resulted
in a significant rebound (“flare”) of cancer cell proliferation
detected by positron emission tomography (PET) imaging in
a mouse model (Nagengast et al., 2011). A withdrawal flare
was also confirmed by PET imaging in 16 patients treated with
sunitinib 50mg/day according to 4/2 or 2/1 schedule (Liu et al.,
2011). Those results could support the continuous dosing of
sunitinib without rest periods as a further attractive alternative
regimen.
It is worth noting that a sigmoidal dose-response curve may
describe the relationships between the systemic exposure to
the drug (as the area-under-the-curve from time 0 up to the
24th hour, AUC0−24h), time to progression (TTP) and overall
survival (OS) in mRCC patients (Houk et al., 2010). In particular,
AUC0−24h-values higher than 1.5 h × mg/L were related to
the highest probability of achieving partial responses (>80%)
and disease stabilization (>95%). Those effective concentrations
were obtained with sunitinib 50 mg/day in 7–14 days of a
2/1 schedule (Britten et al., 2008), during which the mean
AUC-values of the drug increased from 0.341 h ×mg/L on
day 1 up to 1.717 h ×mg/L on day 14. An interesting
finding of the study conducted by Britten and colleagues is
the presence of measurable sunitinib plasma concentrations
at the end of the 7-day rest period (Britten et al., 2008).
It is worth noting that doses of 50mg/day led to a median
value of sunitinib plasma AUC of 1.113 h×mg/L, whereas
sunitinib 75mg/day led to median AUC-values of 2.347 h ×
mg/L (Faivre et al., 2006). Taken into consideration both the
large interindividual variability of sunitinib pharmacokinetics
(Houk et al., 2009) and the non-linear pharmacokinetics of
the drug confirmed in clinical trials (Faivre et al., 2006; Houk
et al., 2010), some patients could be exposed to subtherapeutic
concentrations, whereas an eventual dose escalation should be
cautious. Therefore, regardless the schedule, there is room to
dosage optimization thanks to therapeutic drug monitoring
protocols.
On the basis of the available pharmacokinetic and
pharmacodynamics data one may argue that the 2/1
schedule is an active treatment because sunitinib achieves
effective target plasma concentrations within the range 50–
100 ng/mL (Figure 1), and the exposure is maximized to
obtain a therapeutic effect (i.e., AUC0−24 of approximately
1.5 h × mg/L). Furthermore, the antiproliferative effect of
sunitinib still continues during the rest period of 7 days,
because (1) the drug is still circulating within the blood flow
at the beginning of the next cycle and (2) the final effect
on tumor microvessel density does last for days. At this
point, the improved tolerability of the 2/1 schedule helps to
support its therapeutic advantages with respect to the standard
schedule.
SAFETY PROFILE
Several studies have compared the tolerability of the standard
4/2 schedule with that of the alternative one. Overall, the
conclusion of those studies is the same, with a highly significant
reduction of moderate-to-severe toxic effects, namely diarrhea,
fatigue, mucositis, thrombocytopenia, and hypertension in
the alternative schedule (Bracarda et al., 2015; Gore et al.,
2015). In one of those recent papers, patients were shifted
from the standard to the alternative schedule and the
latter was characterized by a significant improvement in
tolerability (Bracarda et al., 2015). As a consequence, a
greater percentage of patients continued the treatment without
delays or reductions of daily doses, being those events
potentially related to a diminished therapeutic effect. Schnadig
and colleagues drew the same conclusions (Schnadig et al.,
2014), because the occurrence of unmanageable toxicities
caused treatment discontinuation or dose reduction, which
in turn were associated with inferior clinical outcomes with
respect to patients who tolerate sunitinib and remained on
treatment.
At this point, the second question is why the 2/1 schedule
is better tolerated than the 4/2 one. Both treatments have
the same dose intensity in a 6-week period, and both of
them have a rest period that allows patients to recover from
toxicities. However, during a 4/2 schedule, patients start to
experience sunitinib-induced toxicities at the second week of
treatment, and the severity usually increases over the next 2
weeks (Najjar et al., 2014). This means that the probability
to observe a moderate-to-severe toxicity in the 4/2 treatment
is higher in comparison with the alternative schedule 2/1
(Figure 1). In the latter case, sunitinib administration is halted
at day 14, before adverse events could worse, and 1 week
off treatment is likely enough to allow the complete recovery
from mild, low-grade toxic effects. Furthermore, the work of
Houk and colleagues helps to explain this hypothesis through a
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FIGURE 1 | Schematic representation of plasma concentrations (solid lines) and probability of toxicities grade ≥1 (dashed lines) associated with administration of
sunitinib 50mg/day (triangles) according to the standard 4/2 (black lines/triangles), or the alternative 2/1 schedule (gray lines/triangles). Both regimens have the same
dose intensity, but the increased severity of toxicities is associated with the standard schedule. Furthermore, there is the evidence that sunitinib effects may extend up
to 1 week after the last daily dose (post-tx antiangiogenic effects), hence the 1 week of rest in the 2/1 schedule could be beneficial for patients while ensuring the
recovery from mild toxicities. The gray area represents the therapeutic range of sunitinib plasma concentrations (50–100 ng/mL).
mathematical model (Houk et al., 2010). The rate of incidence
and severity of toxicities increases with the length of sunitinib
administration, as it occurs for fatigue. In particular, the increase
in treatment duration from 14 up to 28 days nearly doubled
the probability to experience fatigue ≥1, considering that the
calculated half-life for the appearance of this toxicity is 8
days. Therefore, the better tolerability of the 2/1 schedule
compared with the 4/2 regimen may be attributable to the
lowest probability of occurrence of moderate-to-severe adverse
events.
The last point that should be briefly discussed is the duration
of the rest period with respect to both treatment tolerability
and drug pharmacokinetics. As anticipated above, sunitinib
concentrations are measurable at the end of the 7-day rest
period (Britten et al., 2008). That result was not surprising
because the drug has a long terminal half-life (approximately
70 h), but an accumulation of the drug over the next cycles was
firmly excluded (Britten et al., 2008). Therefore, AUC-values
associated with a higher therapeutic benefit could be achieved
by a 2/1 schedule without increasing the risk of toxic effects
caused by the accumulation of the drug over the entire planned
treatment.
CONCLUSIONS
The recent studies on the alternative schedule 2/1 have
demonstrated an identical efficacy in comparison with the
standard 4/2 treatment because both schedules achieve the
same plasma levels and share the same dose intensity, but
the first one is characterized by a reduced incidence of
moderate-to-severe adverse events (Bracarda et al., 2015). The
improved tolerability is the major difference between the two
schedules. Indeed, mild toxic effects occur with less frequency
in the 2/1 regimen, allow a longer treatment duration and,
consequently, a longer disease control (Bracarda et al., 2015).
On the contrary, any treatment delay or suspension due to
adverse reactions after the 4/2 schedule have been associated
with a reduced therapeutic benefit and inferior clinical outcomes
(Schnadig et al., 2014). Therefore, the better tolerability of the
2/1 schedule increases the possibility of extended treatments,
which do represent a therapeutic advantage for mRCC patients.
It is worth noting that pharmacological data collected in
several preclinical and clinical studies may explain those
observations. While offering new areas for discovering predictive
biomarkers, pharmacodynamic studies have demonstrated that
the antiangiogenic effect of sunitinib follows the short-lived
changes of soluble factors and persists after their normalization
in circulating blood. The post-chemotherapeutic inhibitory
effect on microvessels exerted by sunitinib lasts for a variable
period of time after the cessation of drug administration, its
duration seems to be long enough to cover the rest period
between two consecutive cycles, at least in the 2/1 schedule,
despite a withdrawal flare is possible as confirmed by some
preclinical and clinical studies. Intriguingly, a pharmacodynamic
modeling demonstrated that the increase in toxicity risk doubled
nearly every 8 days (Houk et al., 2010), hence explaining
why a 2-week treatment is devoid of those severe toxicities
reported during the standard schedule. As a consequence, the
majority of patients may recover from mild-grade adverse
reactions during the rest period, even if it only lasts a
week.
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In conclusion, it is really impressive how changing the
schedule of drug administration by splitting the treatment
into two periods has increased tolerability beyond expectancies,
hence demonstrating the possibility to optimize tolerability and
subsequently efficacy by changing the standard regimens in a
rational way.
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